Adverse effects of immunotherapies that are expected in oncology settings are not tolerated in autoimmune and other chronic diseases. Read our whitepaper to learn about key safety and toxicity needs for immunotherapies in non-oncology indications, including the shift from Maximum Tolerated Dosing (MTD) to Optimal Biological Dosing (OBD). https://ow.ly/Mtvz50ZTukS
About us
Since our foundation in Dublin, Ireland in 1990, our mission has been to help our clients to accelerate the development of drugs and devices that save lives and improve quality of life. We do this by delivering best in class information, solutions and performance, with an unyielding focus on quality at all times. We offer a full range of consulting, development and commercialisation services from a global network of offices in 53 countries. We focus our innovation on the factors that are critical to our clients – reducing time to market, reducing cost, and increasing quality – and our global team of experts has extensive experience in a broad range of therapeutic areas.
- Website
-
http://www.iconplc.com
External link for ICON plc
- Industry
- Biotechnology Research
- Company size
- 10,001+ employees
- Headquarters
- Dublin
- Type
- Public Company
- Specialties
- Medical Device, Therapeutics, Government and Public Health Solutions, Clinical Research Services, Commercialisation and Outcomes, Oncology, Value Based Healthcare, Clinical Trials, Patient Recruitment, Innovation, Regulatory Affairs, Strategic Consulting, Medical Affairs, and Global Patient Insights & Engagement
Employees at ICON plc
View 35k employees at ICON plc
or
Locations
Updates
-
Meet ICON at #ESMO26, booth #8005, to discuss how our scientific insight, oncology expertise, connected site network and purpose-built technology can support your program from strategy to study delivery. Explore practical solutions to the challenges shaping oncology development, from advanced modalities to increasing competition for sites and patients. Arrange a meeting with ICON experts at ESMO: https://ow.ly/V1CQ50ZTnMe
-
-
60 colleagues. One shared cause. On 27 September, 60 members of our ICON team in Argentina joined more than 12,500 people in Buenos Aires for the 20th Caminata Avon. Together, they completed the 4.5 km walk in support of breast cancer awareness, helping to highlight the importance of breast health and early detection. We are proud to see so many of our colleagues coming together to support an important cause and bringing the ICON spirit into the communities where we live and work. #ICONCares #CaminataAvon #BreastCancerAwareness #Argentina
-
-
-
-
-
+6
-
-
Single-stop research publication decisioning. PubsHub Journals & Congresses provides everything you need to decide the best place to publish your work. 50+ metadata consideration points including deadlines and lead times on over 10,000 resources. Links to author submission guides. Fast and easy. Get a demo. https://ow.ly/6RnG50ZEofz
-
-
Meet Brittany Savoca at the #GSSS, during the TA Round Table: Neurology & Alzheimer’s on October 16 at 4:45 pm, where she will share lessons learned from successful studies and share insights on fostering collaboration to improve study execution and trial outcomes. https://ow.ly/6aCx50ZKqX9
-
-
The countdown to #OCTNordics is on, and ICON is proud to be sponsoring this year's event in Copenhagen on 20–21 October. Drop by booth #41 to connect with our experts and explore how ICON is driving innovation and operational excellence across clinical development. Whether you're looking to streamline your trial processes, enhance patient engagement, or navigate regulatory complexities, our team is ready to share insights and solutions tailored to your needs. https://ow.ly/jzog50ZIbtu
-
-
How can sponsors generate meaningful clinical insights earlier in neurodegenerative disease development? Join ICON specialists Paula Kopschina Feltes and Matthias Mohse as they explore innovative first-in-human study designs, patient-centric approaches, and biomarker strategies that can support faster, more informed development decisions. Register today: https://ow.ly/llQ050ZLT4K
-
-
A promising biomarker strategy can quickly become a development bottleneck if global implementation isn't planned from the outset. At WorldCDx on 8 October, ICON will discuss how sponsors can avoid common challenges related to biomarker assay development, validation, harmonisation, and CDx readiness. https://ow.ly/pIIZ50ZKjfY Naveen Babbar
-
-
Maintaining patient safety in the real world means more than meeting reporting timelines. It requires strong oversight, robust processes and the ability to adapt as products and markets evolve. At ICON, we understand the importance of post-marketing pharmacovigilance. Our dedicated teams are committed to delivering services that protect patients, ensure global compliance, and lighten the operational load for sponsors. Discover how we support organisations beyond approval: https://ow.ly/yUlk50ZPLxj #Pharmacovigilance #DrugSafety #ClinicalResearch
-
Diagnostics are transforming how diseases are detected, monitored and treated. At ICON, our Medical Device & Diagnostics Research team supports the development of in vitro diagnostics, companion diagnostics and emerging testing technologies through specialised clinical, laboratory and regulatory expertise. If you're attending The MedTech Conference this October, stop by booth #635 to discuss your diagnostic development strategy. https://ow.ly/N7I250ZKrbE #MedTechCon #Diagnostics #IVD #CompanionDiagnostics #PrecisionMedicine #ClinicalResearch
-